Processing

Please wait...

Settings

Settings

Goto Application

1. WO2004091545 - SELECTIVELY INHIBITING ESTROGEN PRODUCTION AND PROVIDING ESTROGENIC EFFECTS IN THE HUMAN BODY

Publication Number WO/2004/091545
Publication Date 28.10.2004
International Application No. PCT/US2004/009129
International Filing Date 25.03.2004
Chapter 2 Demand Filed 25.10.2004
IPC
A61K 31/353 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
352condensed with carbocyclic rings, e.g. cannabinols, methantheline
3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61K 33/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
CPC
A61K 31/353
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
352condensed with carbocyclic rings, e.g. cannabinols, methantheline
3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61K 36/746
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
18Magnoliophyta (angiosperms)
185Magnoliopsida (dicotyledons)
74Rubiaceae (Madder family)
746Morinda
A61P 19/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
08for bone diseases, e.g. rachitism, Paget's disease
10for osteoporosis
A61P 25/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
06Antimigraine agents
A61P 25/26
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
26Psychostimulants, e.g. nicotine, cocaine
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • MORINDA, INC. [US]/[US] (AllExceptUS)
  • PALU, Afa, Kehaati [TO]/[US]
Inventors
  • PALU, Afa, Kehaati
  • WANG, Mian, Ying
  • SU, Chen, Xing
  • WEST, Brett, Justin
  • WESTENDORF, Johannes, Joseph
  • JENSEN, Claude, Jarakae
  • STORY, Stephen, Paul
Agents
  • KRIEGER, Michael, F.
Priority Data
10/396,86825.03.2003US
10/808,87224.03.2004US
60/458,35328.03.2003US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) SELECTIVELY INHIBITING ESTROGEN PRODUCTION AND PROVIDING ESTROGENIC EFFECTS IN THE HUMAN BODY
(FR) INHIBITION SELECTIVE DE LA PRODUCTION D'OESTROGENES ET INDUCTION D'EFFETS OESTROGENIQUES DANS LE CORPS HUMAIN
Abstract
(EN)
Implementation is directed to selectively inhibiting estrogen production and providing estrogenic effects in a human body. A dietary supplement includes a processed Morinda citrifolia product that is used to inhibit aromatase or aromatase enzymes that function to convert androgens to estrogens, inhibit receptors from binding with estrogen, and reduce and/or regulate estrogen production, as well as reduce the amount of estrogen produced within the body and regulating such production. The dietary supplement further provides estrogenic effects. The present invention methods and compositions effectively function to treat estrogen-dependent cancers, and particularly inhibit, destroy, and reverse the effects of of estrogen­dependent cancerous tumors through the introduction into the body (e.g. ingesting) a safe, pre-determined dosage of a naturaceutical composition formulated with or comprising one or more processed Morinda citrifolia products for a safe, pre­determined duration.
(FR)
L'invention concerne l'inhibition sélective de la production d'oestrogènes et l'induction d'effets oestrogéniques dans le corps humain. Un complément alimentaire renferme un produit traité de Morinda citrifolia, utilisé pour inhiber l'aromatase ou les enzymes aromatase qui assurent la conversion d'androgènes en oestrogènes, empêcher les récepteurs de se lier avec les oestrogènes, et réduire et/ou réguler la production oestrogènes, mais aussi réduire la quantité oestrogènes produite dans le corps et réguler cette production. Ledit complément induit par ailleurs des effets oestrogéniques. L'invention concerne également des procédés et des compositions efficaces pour traiter les cancers qui dépendent des oestrogènes, et en particulier inhiber, détruire et inverser les effets des tumeurs cancéreuses qui dépendent des oestrogènes, par introduction dans le corps (par exemple, ingestion) d'une dose sûre préétablie de composition pharmaceutique formulée avec un ou plusieurs produits traités de Morinda citrifolia, ou comprenant ces produits, pendant une durée sûre préétablie.
Latest bibliographic data on file with the International Bureau